Loading
Latest filing published 04 May 2023 for Jounce Therapeutics, Inc..
No signal scores available.
Robert Kamen appears in our data through filings on Jounce Therapeutics, Inc. shares, published by SEC (Form 4). In total, 2 filings cover trades dated 3 May 2023.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Most recently, on 4 May 2023, the filings show a transaction in Jounce Therapeutics, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations